Cabazitaxel for the treatment of castration-resistant prostate cancer

Future Oncol. 2011 Jan;7(1):15-24. doi: 10.2217/fon.10.168.


Treatment with docetaxel-based chemotherapy results in improved survival in patients with metastatic castration-resistant prostate cancer. However, all patients eventually develop progressive disease associated with poor outcomes. In this article, we discuss the available second-line therapeutic options following docetaxel, with a special focus on cabazitaxel, which is the first agent to yield extended survival as second-line therapy following docetaxel. Cabazitaxel, a novel semi-synthetic taxane, is effective even in docetaxel-resistant model systems. Recently, results of the Phase III TROPIC trial demonstrated improved survival with cabazitaxel plus prednisone compared with mitoxantrone and prednisone in patients with progressive metastatic castration-resistant prostate cancer, following prior docetaxel, which led to approval by the US FDA.

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Aged
  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Caco-2 Cells
  • Castration
  • Clinical Trials, Phase III as Topic
  • Drug Therapy, Combination
  • HL-60 Cells
  • Humans
  • Leukemia P388
  • Male
  • Mice
  • Middle Aged
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / secondary
  • Prostatic Neoplasms / surgery
  • Survival Analysis
  • Taxoids / adverse effects
  • Taxoids / pharmacokinetics
  • Taxoids / therapeutic use*
  • Treatment Outcome


  • Adrenal Cortex Hormones
  • Antineoplastic Agents
  • Taxoids
  • cabazitaxel